RF Lung Ablation Associated With Deaths, FDA Says
This article was originally published in The Gray Sheet
Executive Summary
A Dec. 11 FDA health notice links several patient deaths to radiofrequency ablation of lung tumors and notes that the uses were off-label
You may also be interested in...
Lung Tumor RF Ablation Trials Should Assess Survival Benefit – FDA Panel
Survival rates following lung tumor treatment with RITA Medical Systems' StarBurst radiofrequency (RF) ablation device should be assessed at one year, FDA's General & Plastic Surgery Devices Panel recommends
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.